CAS Number 445430-58-0 IUPHAR/BPS 5669 UNII 26SU0NEF5F Molar mass 255.3 g/mol | PubChem CID 9813758 ChemSpider 7989508 ChEMBL CHEMBL249697 | |
 | ||
BMS-345541, marketed by Merck KGaA, is an anti-inflammatory, cell-permeable quinoxaline compound. It is an allosteric site-binding inhibitor with a primary target of IKK-2 and blocks the NF-κB-dependent transcription in mice.
It has no approvals for human/medical use or for use in clinical trials. No clinical trials mention it.
References
BMS-345541 Wikipedia(Text) CC BY-SA